Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Physiol ; 589(Pt 8): 2007-26, 2011 Apr 15.
Artigo em Inglês | MEDLINE | ID: mdl-21320889

RESUMO

The muscle wasting and impaired muscle function in critically ill intensive care unit (ICU) patients delay recovery from the primary disease, and have debilitating consequences that can persist for years after hospital discharge. It is likely that, in addition to pernicious effects of the primary disease, the basic life support procedures of long-term ICU treatment contribute directly to the progressive impairment of muscle function. This study aims at improving our understanding of the mechanisms underlying muscle wasting in ICU patients by using a unique experimental rat ICU model where animals are mechanically ventilated, sedated and pharmacologically paralysed for duration varying between 6 h and 14 days. Results show that the ICU intervention induces a phenotype resembling the severe muscle wasting and paralysis associated with the acute quadriplegic myopathy (AQM) observed in ICU patients, i.e. a preferential loss of myosin, transcriptional down-regulation of myosin synthesis, muscle atrophy and a dramatic decrease in muscle fibre force generation capacity. Detailed analyses of protein degradation pathways show that the ubiquitin proteasome pathway is highly involved in this process. A sequential change in localisation of muscle-specific RING finger proteins 1/2 (MuRF1/2) observed during the experimental period is suggested to play an instrumental role in both transcriptional regulation and protein degradation. We propose that, for those critically ill patients who develop AQM, complete mechanical silencing, due to pharmacological paralysis or sedation, is a critical factor underlying the preferential loss of the molecular motor protein myosin that leads to impaired muscle function or persisting paralysis.


Assuntos
Cuidados Críticos , Imobilização/efeitos adversos , Músculo Esquelético/metabolismo , Atrofia Muscular/metabolismo , Paralisia/metabolismo , Miosinas de Músculo Esquelético/metabolismo , Análise de Variância , Animais , Modelos Animais de Doenças , Regulação para Baixo , Feminino , Contração Muscular , Proteínas Musculares/metabolismo , Força Muscular , Músculo Esquelético/patologia , Músculo Esquelético/fisiopatologia , Atrofia Muscular/etiologia , Atrofia Muscular/genética , Atrofia Muscular/patologia , Atrofia Muscular/fisiopatologia , Bloqueadores Neuromusculares/administração & dosagem , Paralisia/etiologia , Paralisia/genética , Paralisia/patologia , Paralisia/fisiopatologia , Fenótipo , Complexo de Endopeptidases do Proteassoma/metabolismo , Biossíntese de Proteínas , Transporte Proteico , RNA Mensageiro/metabolismo , Ratos , Ratos Sprague-Dawley , Respiração Artificial , Miosinas de Músculo Esquelético/genética , Fatores de Tempo , Transcrição Gênica , Proteínas com Motivo Tripartido , Ubiquitina-Proteína Ligases/metabolismo , Ubiquitinação , Suporte de Carga
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...